Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
In vivo knockdown of TAK1 accelerates bone marrow proliferation/differentiation and induces systemic inflammation.
Vink PM, Smout WM, Driessen-Engels LJ, de Bruin AM, Delsing D, Krajnc-Franken MA, Jansen AJ, Rovers EF, van Puijenbroek AA, Kaptein A, Nolte MA, Garritsen A, van Eenennaam H. Vink PM, et al. Among authors: van puijenbroek aa, van eenennaam h. PLoS One. 2013;8(3):e57348. doi: 10.1371/journal.pone.0057348. Epub 2013 Mar 7. PLoS One. 2013. PMID: 23505428 Free PMC article.
Human TLR10 is an anti-inflammatory pattern-recognition receptor.
Oosting M, Cheng SC, Bolscher JM, Vestering-Stenger R, Plantinga TS, Verschueren IC, Arts P, Garritsen A, van Eenennaam H, Sturm P, Kullberg BJ, Hoischen A, Adema GJ, van der Meer JW, Netea MG, Joosten LA. Oosting M, et al. Among authors: van eenennaam h, van der meer jw. Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):E4478-84. doi: 10.1073/pnas.1410293111. Epub 2014 Oct 6. Proc Natl Acad Sci U S A. 2014. PMID: 25288745 Free PMC article.
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC. Tai YT, et al. Among authors: van eenennaam h, van elsas a. Blood. 2016 Jun 23;127(25):3225-36. doi: 10.1182/blood-2016-01-691162. Epub 2016 Apr 28. Blood. 2016. PMID: 27127303 Free PMC article.
Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint.
Voets E, Paradé M, Lutje Hulsik D, Spijkers S, Janssen W, Rens J, Reinieren-Beeren I, van den Tillaart G, van Duijnhoven S, Driessen L, Habraken M, van Zandvoort P, Kreijtz J, Vink P, van Elsas A, van Eenennaam H. Voets E, et al. Among authors: van duijnhoven s, van eenennaam h, van zandvoort p, van elsas a, van den tillaart g. J Immunother Cancer. 2019 Dec 4;7(1):340. doi: 10.1186/s40425-019-0772-0. J Immunother Cancer. 2019. PMID: 31801627 Free PMC article.
Integrated Single-Cell (Phospho-)Protein and RNA Detection Uncovers Phenotypic Characteristics and Active Signal Transduction of Human Antibody-Secreting Cells.
van Buijtenen E, Janssen W, Vink P, Habraken MJM, Wingens LJA, van Elsas A, Huck WTS, van Buggenum JAGL, van Eenennaam H. van Buijtenen E, et al. Among authors: van eenennaam h. Mol Cell Proteomics. 2023 Feb;22(2):100492. doi: 10.1016/j.mcpro.2023.100492. Epub 2023 Jan 7. Mol Cell Proteomics. 2023. PMID: 36623694 Free PMC article.
Biophysical and Immunological Characterization and In Vivo Pharmacokinetics and Toxicology in Nonhuman Primates of the Anti-PD-1 Antibody Pembrolizumab.
Hutchins B, Starling GC, McCoy MA, Herzyk D, Poulet FM, Dulos J, Liu L, Kang SP, Fayadat-Dilman L, Hsieh M, Andrews CL, Ayanoglu G, Cullen C, Malefyt RW, Kastelein RA, Saux SL, Lee J, Li S, Malashock D, Sadekova S, Soder G, van Eenennaam H, Willingham A, Yu Y, Streuli M, Carven GJ, van Elsas A. Hutchins B, et al. Among authors: van eenennaam h, van elsas a. Mol Cancer Ther. 2020 Jun;19(6):1298-1307. doi: 10.1158/1535-7163.MCT-19-0774. Epub 2020 Mar 30. Mol Cancer Ther. 2020. PMID: 32229606
Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy.
Guelen L, Fischmann TO, Wong J, Mauze S, Guadagnoli M, Bąbała N, Wagenaars J, Juan V, Rosen D, Prosise W, Habraken M, Lodewijks I, Gu D, Stammen-Vogelzangs J, Yu Y, Baker J, Lutje Hulsik D, Driessen-Engels L, Malashock D, Kreijtz J, Bertens A, de Vries E, Bovens A, Bramer A, Zhang Y, Wnek R, Troth S, Chartash E, Dobrenkov K, Sadekova S, van Elsas A, Cheung JK, Fayadat-Dilman L, Borst J, Beebe AM, Van Eenennaam H. Guelen L, et al. Among authors: van eenennaam h. J Immunother Cancer. 2022 Sep;10(9):e005049. doi: 10.1136/jitc-2022-005049. J Immunother Cancer. 2022. PMID: 36100308 Free PMC article.
39 results